After overcoming the core bottleneck of high-sensitivity CTC capture and in vitro amplification, we further established a CTC drug sensitivity testing platform based on the patient's own tumor cells. This platform can directly use the amplified tumor cells for drug screening, accurately reflecting the drug response characteristics of individual tumors, avoiding biases caused by biological differences between traditional cell lines and patient tumors, reducing trial-and-error costs, and improving the accuracy of clinical treatment decisions.

Based on a self-developed biomimetic tumor microenvironment chip, circulating tumor cells (CTCs) derived from the patient's peripheral blood are combined with a customized hydrogel matrix, and a three-dimensional co-culture system is constructed through microfluidic technology to simulate the in vivo tumor niche (including hypoxia gradients, vasculature-mimicking structures, and stromal cell interactions), achieving in situ expansion and functional maintenance of CTCs.

• 
• 

  Integrated workflow

  From sample to report on a systematic platform

• 

  Efficient rare cell enrichment

  Achieve comprehensive capture of various types of cells

• 

  Flexible downstream applications

  Drug testing, gene analysis, and target validation

• 

  Executable data output

  Support clinical decision-making and R&D strategy formulation

• 

  AI-driven analysis

  Fast, automated cell identification and quantification

• Sample Collection

  

• Labyrinth®
  Platform Enriched CTCs

  

• Fluorescent Staining Identification

  

• Ai AI Software Rare Cell Counting

  

• Cell Line Culture

  

• Drug Sensitivity Testing